Lawyers for patients suing Johnson & Johnson and Bayer allege that the companies misled editors at The New England Journal of Medicine about the safety of rivaroxaban (Xarelto), the New York Times reports.
The attorneys allege that Duke University researchers left out critical laboratory data. Johnson & Johnson and Duke said they worked independently, while Bayer declined to comment. Sales of rivaroxaban, an oral anticoagulant, were nearly $2 billion in the U.S. last year.
Click below for the full story:
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.